Rituximab，a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis，complement activation and antibody dependent cellular cytotoxicity. Rituximab is a mainstay in the therapy for a broad variety of B-cell malignancies.
